scholarly journals Introduction to the special section on hepatocellular carcinoma treatment response

2021 ◽  
Author(s):  
Mishal Mendiratta-Lala ◽  
Vahid Yaghmai
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Special Section

The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma

2019 ◽  
Author(s):  
Shuaishuai Zhang ◽  
Weiwei Gao ◽  
Juan Tang ◽  
Huaifang Zhang ◽  
Yuqi Zhou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Sorafenib Treatment ◽  
Retinoid Signaling ◽  
Gsk 3Β

Artificial intelligence in assessment of hepatocellular carcinoma treatment response

2021 ◽  
Author(s):  
Bradley Spieler ◽  
Carl Sabottke ◽  
Ahmed W. Moawad ◽  
Ahmed M. Gabr ◽  
Mustafa R. Bashir ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Hepatocellular Carcinoma ◽  
Treatment Response

Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy

2021 ◽  
Vol 29 (3) ◽  
pp. 389-403
Author(s):  
Rony Kampalath ◽  
Karen Tran-Harding ◽  
Richard K.G. Do ◽  
Mishal Mendiratta-Lala ◽  
Vahid Yaghmai
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Locoregional Therapy

Serum neutrophil/lymphocyte ratio as a potential predictor of treatment response for immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16156-e16156
Author(s):  
Jian He ◽  
Zhiqiang Mo ◽  
Qicong Mai ◽  
Xiaoming Chen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Post Treatment ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
Lymphocyte Ratio ◽  
Pre Treatment

e16156 Background: Neutrophil to lymphocyte ratio (NLR) has been shown to associate with tumor progression. The present study was to investigate the role of NLR on predicting the treatment response for immune checkpoint inhibitors (ICIs) therapy in patients with advanced hepatocellular carcinoma (HCC). Methods: We retrospectively reviewed 81 patients received ICIs for advanced HCC from January 2017 to July 2019. We analyzed whether pre- and first 3 weeks post- treatment serum NLR level was associated with ICIs outcome. Results: In this study, the pre-treatment NLR level ranged from 0.64 to 14.93 among 81 patients. The cut-off level of NLR was set as the median value of 2.79. The objective response rate (ORR) in the patients with NLR＜2.79 (low NLR) was 25.0%, which was significantly better than that of patients with NLR ≥2.79 (high NLR) (7.3%, P ＝0.03). Compared to patients with high NLR, patients with low NLR exhibited significantly longer median progression-free survival (PFS) (3.7 vs 3.0 months, P ＝0.004) and median overall survival (OS) (10.3 vs 7.5 months, P ＝0.001). Multivariate analysis revealed high NLR was an independent unfavourable prognostic factor for PFS (hazard ratio [HR] = 1.857, 95% confidence interval [CI] = 1.093-3.154; P = 0.022) and OS (HR = 2.267, 95% CI = 1.221-4.207; P = 0.009). For the patients with high pre-treatment NLR level, ICIs outcome was stratified more clearly by first 3 weeks post- treatment NLR level. Conclusions: The pre- and first 3 weeks post- treatment serum NLR level could be considered as a predictive factor of treatment response for ICIs in patients with advanced HCC.

scholarly journals Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017

2020 ◽  
Vol 30 (1) ◽  
pp. 261-271 ◽  
Author(s):  
Nieun Seo ◽  
Myoung Soo Kim ◽  
Mi-Suk Park ◽  
Jin-Young Choi ◽  
Richard K. G. Do ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Data System ◽  
Liver Imaging ◽  
Explanted Liver
Sign in / Sign up

Export Citation Format

Share Document